Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K251087
    Manufacturer
    Date Cleared
    2025-08-04

    (117 days)

    Product Code
    Regulation Number
    N/A
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    Blood Volume Analyzer (200)

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Daxor BVA-200 is an automated system that is used to measure/calculate the red cell mass (mL), plasma volume (mL) and total blood volume (mL), along with the related deviations from ideal values by amount (mL) and percentage (%) in adults. In addition, the Normalized Hematocrit (%) and Albumin Transudation Rate (%/min) are calculated. It is an in vitro medical device composed of a microprocessor, software, touchscreen, and gamma counter and accessory convenience kit.

    The Daxor BVA-200 is intended to calculate human blood volumes by the method of tracer diffusion (Indicator dilution technique) with I-131 as the tracer after injection of I-131 Human Serum Albumin. The Daxor BVA-200 provides a Quantitative Assessment of total blood and plasma volumes using an automated system.

    Data inputs to the software come from the measured characteristics of patient venous whole blood samples collected in K3EDTA vacutainer tubes (hematocrit and tracer concentration) and tracer calibration standards. The patient blood samples and the calibration standards are measured in a gamma counter, whose output is automatically input to this calculation program. The package also calculates the patient expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, and associated red cell volumes are reported, with statistics showing the quality of the results.

    For in vitro diagnostic use in a Clinical Laboratory setting and operated by laboratory technicians.

    Rx use only.

    Device Description

    The Daxor BVA-200 is an automated system that is used to calculate the red cell mass, plasma volume and total blood volume. It is an in vitro medical device composed of a microprocessor, software, touchscreen, and gamma counter. The accessory convenience kit includes single-use whole blood cartridges and protective sleeves.

    The Daxor BVA-200 is designed to calculate human blood volume, using the method of tracer dilution, utilizing tagged serum albumin (I-131, resulting in "I-HSA"). Data inputs to the software come from the measured characteristics of patient blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the patient expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, and associated red cell volumes, are reported, with statistics showing the quality of the results.

    The patient blood samples and the calibration standards are measured in a gamma counter, whose output is automatically input to this calculation program.

    The BVA-200 has a touchscreen for operator interaction, and provides clear instructions and prompts for the steps necessary for performing the test.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study information for the Daxor Blood Volume Analyzer (200), based on the provided FDA 510(k) clearance letter.

    1. Table of Acceptance Criteria and Reported Device Performance

    The document does not explicitly state "acceptance criteria" in a tabulated format. However, it provides performance metrics from a clinical comparison study and precision, linearity, carryover, and stability studies. The implicit acceptance criteria are that the device performance should be substantially equivalent to the predicate device and demonstrate acceptable precision and linearity.

    Implicit Acceptance Criteria and Reported Device Performance for BVA-200 (vs. BVA-100)

    MeasureAcceptance Criteria (Implicit, based on substantial equivalence)Reported Device Performance (vs. Predicate BVA-100)
    Clinical Comparison (Regression Analysis)Strong correlation, slope near 1, intercept near 0, narrow 95% CI covering 1 for slope and 0 for intercept.
    TBV (Total Blood Volume)-Passing-Bablok Slope: 1.031 (95% CI: 1.014 to 1.049), Intercept: -138 (-235 to -59), Pearson r: 0.99
    Deming Slope: 1.033 (95% CI: 1.017 to 1.050), Intercept: -153 (-241 to -69), Pearson r: 0.99
    RCV (Red Cell Volume)-Passing-Bablok Slope: 1.016 (95% CI: 1.002 to 1.030), Intercept: -25 (-50 to 2), Pearson r: 0.99
    Deming Slope: 1.024 (95% CI: 1.008 to 1.040), Intercept: -37 (-68 to -10), Pearson r: 0.99
    PV (Plasma Volume)-Passing-Bablok Slope: 1.033 (95% CI: 1.016 to 1.051), Intercept: -99 (-155 to -46), Pearson r: 0.99
    Deming Slope: 1.029 (95% CI: 1.014 to 1.046), Intercept: -83 (-138 to -32), Pearson r: 0.99
    nHct (Normalized Hematocrit)-Passing-Bablok Slope: 1.007 (95% CI: 0.982 to 1.032), Intercept: -0.19 (-1.18 to 0.77), Pearson r: 0.98
    Deming Slope: 1.022 (95% CI: 0.999 to 1.047), Intercept: -0.76 (-1.71 to 0.21), Pearson r: 0.98
    Precision (Total Precision %CV)(Implicitly) Low %CV, indicating high precision.All total precision %CV results were below 3.6%.
    Linearity(Implicitly) Strong correlation with expected values, low bias, and CV for repeatability ≤5%, max deviation from linearity ≤8%.Global Slope near 1 (range 1.00-1.02), Mean Bias Percent low (range 0.37-0.41).
    For contrived samples (2000-18000 ml): CV for repeatability ≤5%, Max deviation from linearity ≤8%.
    CarryoverNo carryover observed.No carryover observed.
    Sample StabilityImpervious to temperature/humidity, decay matches I-131, withstands shipping, non-level operation up to 15 degrees, settling does not affect readings, stability for 4 days (refrigerated/room temp).All stated conditions were met. "No significant differences were observed, nor was there any significant drift of measurements observed."
    Handling (Cartridge drop test)Performance criteria still met after drop.None of the average measured parameters differed from pre-drop by more than 2.7%.
    Handling (Shipping & Handling)Resistance to breakage and radio-emission stability. Sample and device integrity maintained.None of the average measured parameters differed from pre-ship by more than 3.1%.
    Handling (Tilt position)Stable measurement at non-level positioning up to 15 degrees.None of the average measured parameters differed from pre-ship by more than 3.1%.
    Interference (Hemolysis)Results not affected by hemolysis.Partial hemolysis: -0.72% ± 0.77% difference from baseline. Gross hemolysis: -0.14% ± 2.16% difference from baseline.

    2. Sample Size Used for the Test Set and Data Provenance

    • Sample Size for Test Set: 319 unique, independent, comparable measurements.
    • Data Provenance:
      • Blood derived from patients undergoing blood volume measurement with the BVA-100 (predicate device) as part of their clinical treatment or as part of a research study.
      • The document implies the data is retrospective for the clinical comparison, as it used blood derived from patients undergoing measurement with the predicate device.
      • For precision, linearity, sample stability, handling, and interference studies, contrived samples and venous whole blood samples from male and female volunteers were used. No specific country of origin is mentioned.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

    The document does not mention the use of experts to establish ground truth for the test set in the context of a reader study or image interpretation. The ground truth for the clinical comparison study was established by the predicate device (Daxor BVA-100) measurements.

    4. Adjudication Method for the Test Set

    Not applicable. The ground truth for the clinical comparison was based on measurements from the predicate device, not expert adjudication of subjective assessments.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

    No, an MRMC comparative effectiveness study was not done. This device is a quantitative measurement system, not an AI software intended for interpretation by human readers. The clinical study focused on comparing the performance of the new device (BVA-200) to its predicate (BVA-100) on quantitative measurements.

    6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done

    Yes, the studies performed focused on the standalone performance of the BVA-200. The device is an automated system that measures and calculates blood volumes. The performance data presented (clinical comparison, precision, linearity, stability, etc.) represents the device's output independently, without human interpretation as part of a "human-in-the-loop" workflow being evaluated.

    7. The Type of Ground Truth Used

    The ground truth for the primary clinical comparison study was the measurements obtained from the predicate device, the Daxor BVA-100. For other studies (precision, linearity, stability, etc.), the ground truth was based on known properties of contrived samples or established physical/biological principles (e.g., known decay rate of I-131).

    8. The Sample Size for the Training Set

    The document does not provide information on a training set sample size. This suggests that the BVA-200, similar to its predicate BVA-100, is likely based on established physiological and radiological principles (indicator dilution technique, I-131 decay) rather than a machine learning model that requires a distinct "training set." The software performs calculations based on these principles and measured inputs, not through a learned model from a training set.

    9. How the Ground Truth for the Training Set Was Established

    Not applicable, as a "training set" in the context of machine learning is not implied or described in the document for this device.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1